News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Organovo, Inc.
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
May 08, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces FXR Program
March 21, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close